NVCR logo

NVCR
NovoCure Ltd

7,743
Mkt Cap
$1.89B
Volume
3.65M
52W High
$20.06
52W Low
$9.82
PE Ratio
-10.83
NVCR Fundamentals
Price
$16.62
Prev Close
$15.21
Open
$15.48
50D MA
$12.23
Beta
1.48
Avg. Volume
1.41M
EPS (Annual)
-$1.22
P/B
5.82
Rev/Employee
$408,319.63
$1,232.17
Loading...
Loading...
News
all
press releases
NovoCure (NASDAQ:NVCR) Trading 6.8% Higher - Should You Buy?
NovoCure (NASDAQ:NVCR) Stock Price Up 6.8% - Here's Why...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
NovoCure (NASDAQ:NVCR) Announces Earnings Results
NovoCure (NASDAQ:NVCR - Get Free Report) released its quarterly earnings results on Thursday. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.13). The business had revenue of $174.06 million for the quarter...
MarketBeat·3d ago
News Placeholder
NovoCure (NVCR) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·3d ago
News Placeholder
NovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy?
NovoCure (NASDAQ:NVCR) Shares Gap Up - Time to Buy...
MarketBeat·3d ago
News Placeholder
Caterpillar Posts Upbeat Q1 Results, Joins Garrett Motion, Wesco International, TTM Technologies And Other Big Stocks Moving Higher On Thursday
US stocks mixed, Dow up 400 pts. Caterpillar, Bandwidth, Everspin, Vistance, IMPINJ, Novocure, Viavi, Garrett, Hertz, Ranpak all gain in Q1.read more...
Benzinga·3d ago
News Placeholder
NovoCure Q1 Earnings Call Highlights
NovoCure (NASDAQ:NVCR) reported first-quarter 2026 results highlighted by double-digit year-over-year growth in both active patients and net revenue, driven in part by strength outside the U.S. and an early commercial ramp for its newly approved pancreatic cancer therapy. Executive Chairman Bill Doy...
MarketBeat·3d ago
News Placeholder
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga·3d ago
News Placeholder
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Novocure Reports First Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most...
Business Wire·3d ago
News Placeholder
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts
Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendatio...
MarketBeat·9d ago
<
1
2
...
>

Latest NVCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.